AGL 7.91 Decreased By ▼ -0.09 (-1.13%)
ANL 11.30 Decreased By ▼ -0.02 (-0.18%)
AVN 84.74 Increased By ▲ 1.29 (1.55%)
BOP 6.24 Increased By ▲ 0.39 (6.67%)
CNERGY 5.69 Decreased By ▼ -0.16 (-2.74%)
EFERT 79.70 Decreased By ▼ -0.40 (-0.5%)
EPCL 65.58 Decreased By ▼ -1.71 (-2.54%)
FCCL 15.00 Decreased By ▼ -0.20 (-1.32%)
FFL 7.11 Increased By ▲ 0.07 (0.99%)
FLYNG 7.70 Decreased By ▼ -0.07 (-0.9%)
GGGL 11.70 Decreased By ▼ -0.20 (-1.68%)
GGL 17.39 Decreased By ▼ -0.26 (-1.47%)
GTECH 9.35 Increased By ▲ 0.17 (1.85%)
HUMNL 7.25 Increased By ▲ 0.05 (0.69%)
KEL 3.47 Decreased By ▼ -0.03 (-0.86%)
LOTCHEM 30.30 Decreased By ▼ -0.65 (-2.1%)
MLCF 28.40 Decreased By ▼ -0.12 (-0.42%)
OGDC 84.60 Decreased By ▼ -0.60 (-0.7%)
PAEL 16.99 Decreased By ▼ -0.12 (-0.7%)
PIBTL 6.13 Decreased By ▼ -0.02 (-0.33%)
PRL 19.49 Decreased By ▼ -0.35 (-1.76%)
SILK 1.29 No Change ▼ 0.00 (0%)
TELE 12.07 Increased By ▲ 0.02 (0.17%)
TPL 9.15 Decreased By ▼ -0.01 (-0.11%)
TPLP 20.20 Increased By ▲ 0.01 (0.05%)
TREET 26.99 Decreased By ▼ -0.11 (-0.41%)
TRG 96.86 Decreased By ▼ -0.44 (-0.45%)
UNITY 23.02 Increased By ▲ 0.19 (0.83%)
WAVES 13.30 Increased By ▲ 0.01 (0.08%)
WTL 1.46 Increased By ▲ 0.01 (0.69%)
BR100 4,338 Decreased By -23.6 (-0.54%)
BR30 15,953 Decreased By -55.9 (-0.35%)
KSE100 43,274 Decreased By -207.5 (-0.48%)
KSE30 16,389 Decreased By -86.8 (-0.53%)
World

US to authorize Pfizer vaccine for age 12 and up: report

  • The people most eager to get their shots have, for the most part, already rolled up their sleeves and done so.
Published May 4, 2021

WASHINGTON: The United States is expected to authorize the Pfizer-BioNTech Covid-19 vaccine for children age 12 and up by early next week, US media reported Monday.

Pfizer has applied for emergency use authorization for its Covid vaccine for children and teenagers between ages 12 and 15, according to CNN, citing a government official.

"The FDA will have to amend the emergency use authorization for the vaccine, but the process should be straightforward," CNN reported.

The US Food and Drug Administration is expected to grant that approval by early next week. After the FDA decision, the Centers for Disease Control and Prevention advisory committee will meet to recommend how the vaccine should be used.

A spokeswoman for the FDA declined to give details on the approval timeline, telling The Washington Post: "We are working to review this request as quickly and transparently as possible."

The Pfizer vaccine is currently authorized for people 16 and older in the United States.

The US pharmaceutical giant said in late March it had submitted data from a clinical trial of 2,260 12- to 15-year-olds that showed the vaccine was highly effective and well-tolerated.

Further testing on younger children is ongoing.

Moderna is conducting trials of its vaccine in teens, with results expected in the summer, as well as in younger children.

Johnson & Johnson is also planning pediatric trials for its vaccine.

Expanding vaccine authorization to include adolescents could open up the US mass vaccination program to millions more people.

The national vaccination rate peaked around April 11, according to official data, and although 55 percent of US adults now have had one or more doses, there's still a long way to go to achieve population immunity against Covid.

The people most eager to get their shots have, for the most part, already rolled up their sleeves and done so.

But vaccine hesitancy remains a major obstacle: a large percentage of US adults don't plan to get the shot and could potentially refuse to get their children vaccinated.

Among Republican voters, 29 percent say they will never take the vaccine, compared to five percent of Democrats and nine percent of independents, according to a recent survey by the Kaiser Family Foundation.

Comments

Comments are closed.